Hyperion Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Hyperion Therapeutics, Inc.
Amylyx is funding research at the Sunnybrook Research Institute to investigate Bax and Bak inhibition in neurodegenerative disease. Repertoire looks into HPV+ cancer with Memorial Sloan Kettering.
French biotech brings candidate for Gaucher and Parkinson’s disease in-house under 2020 pact with Weizmann. Cellevolve, Seattle Children’s partner on cell therapies for CNS cancers.
Under deal amendment, Innovent gets Asia rights to Cyramza, Retevmo and pirtobrutinib.
The company explained during its recent business review how its R&D organization is pursuing the strategic objectives of improving success rates, reducing cycle times and enabling access to novel drugs.
- Other Names / Subsidiaries
- Andromeda Biotech Ltd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.